Immune checkpoint inhibitors (ICIs) have reshaped cancer therapy. ICIs enhance T cell
activation through various mechanisms and may help reverse the exhausted phenotype of …

Simple Summary This review article addresses the toxic effects on the heart associated with
the use of certain cancer-treating drugs known as immune checkpoint inhibitors. These …

Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte antigen 4,
programmed cell death-1, and PD-ligand 1 have revolutionized cancer treatment, achieving …

Immune checkpoint inhibitors (ICIs) are an important advancement in the field of cancer
treatment, significantly improving the survival of patients with a series of advanced …

This study was to scientifically and systematically explore the association between
cardiotoxicity and immune checkpoint inhibitors (ICIs) and also to characterize the spectrum …

Background Vascular endothelial growth factor (VEGF) plays a role in the tumor
microenvironment. Sorafenib, which inhibits the VEGF pathway, has an immune-modulation …

Background Immune checkpoint inhibitors (ICIs) have revolutionized the management of
multiple tumors, due to improved efficacy, quality of life, and safety. While most immune …

Background We performed a systematic review and meta-analysis to evaluate the risks of
cardiac adverse events in solid tumor patients treated with monotherapy of immune …

Immune checkpoint inhibitors (ICIs) are specific monoclonal antibodies directed against
inhibitory targets of the immune system, mainly represented by programmed death-1 (PD1) …

The interaction between programmed cell death protein 1 (PD-1) and its ligand programmed
death-ligand 1 (PD-L1) induces exhaustions of cytotoxic lymphocytes in the tumor …